Physician profile
Varun Modi
NPI 1295126670
$1,804.35
in general payments reported to CMS, 2019-2025
27 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $115 · 2021: $43.03 · 2022: $103 · 2023: $368 · 2024: $524 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,056.92 |
| Education | $151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $359.26 | 2023-2025 | |
| Tempus Ai, INC | $171.10 | 2024-2025 | Xt Cdx |
| Array Biopharma INC | $150.69 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Novartis Pharmaceuticals Corporation | $147.48 | 2019-2023 | |
| Janssen Biotech, INC. | $127.28 | 2022-2023 | Darzalex |
| Amgen INC. | $91.48 | 2019-2023 | Kyprolis |
| Astrazeneca Pharmaceuticals LP | $79.71 | 2019-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $78.48 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $76.82 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $71.18 | 2022-2024 | |
| Celgene Corporation | $44.63 | 2020-2025 | Reblozyl |
| Kite Pharma, INC. | $43.43 | 2022-2023 | |
| Genzyme Corporation | $40.59 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $36.76 | 2019-2020 | |
| Astellas Pharma US INC | $36.59 | 2020-2024 | Vyloy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.79 | 2019-2025 | Ultomiris |
| Genentech USA, INC. | $27.15 | 2019 | |
| Gilead Sciences, INC. | $24.78 | 2023 | |
| Janssen Scientific Affairs, LLC | $23.29 | 2025 | Darzalex, Talvey, Tecvayli |
| Eisai INC. | $22.18 | 2021 | |
| Blue Earth Diagnostics | $20.85 | 2021 | |
| Daiichi Sankyo INC. | $19.93 | 2024 | Enhertu |
| Sobi, INC | $19.85 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2019 | |
| Menarini Silicon Biosystems, INC. | $16.32 | 2025 | |
| Incyte Corporation | $14.68 | 2019 | |
| Btg International INC. | $13.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varun Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.